Search results
To align with PDUFA VII , BsUFA III, and GDUFA III requirements as well as make other improvements to data quality and ease of use, FDA has revised form 356h: Application to Market a New...
- Forms
Listing of all external Forms both OMB approved and state...
- Forms
Learn how to complete the FDA 356h form for new or abbreviated drug or biologic applications. Find out the fields, information, and requirements for each type of submission, such as original, labeling, CMC, or eficacy supplement.
To apply to market a new drug, biologic, or an antibiotic drug for human use, you need to complete Form 356h. Form 356h includes information such as applicant information, proposed indication,...
FORM FDA 356h. Next Page. Export Data. Import Data. Reset Form. DEPARTMENT OF HEALTH AND HUMAN SERVICES Form Approved: OMB No. 0910-0338. Food and Drug Administration Expiration Date: March 31, 2020. APPLICATION TO MARKET A NEW OR ABBREVIATED NEW See PRA Statement on page 3. DRUG OR BIOLOGIC FOR HUMAN USE 1.
Import Data. Reset Form. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Food and Drug Administration. APPLICATION TO MARKET A NEW OR ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE. (Title 21, Code of Federal Regulations, Parts 314 & 601) Form Approved: OMB No. 0910-0338 Expiration Date: December 31, 2013. See PRA Statement on page 3.
Listing of all external Forms both OMB approved and state using ORA forms.
13 lip 2023 · The updated FDA 356H form brings to the table significant improvements from the older form, enhancing the overall quality of drug and biological applications submitted to the USFDA. The updated form includes new sections on chemistry, manufacturing, and controls (CMC), pre-clinical and clinical studies, labeling, and post-marketing safety ...